Search results
Results from the WOW.Com Content Network
In pharmacology, the fibrates are a class of amphipathic carboxylic acids and esters. They are derivatives of fibric acid (phenoxyisobutyric acid). They are used for a range of metabolic disorders, mainly hypercholesterolemia (high cholesterol ), and are therefore hypolipidemic agents .
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL. It was patented in 1971 and approved for medical use in 1978. [1]
Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins.
It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells. [3] Gemfibrozil was patented in 1968, and came into medical use in 1982. [6] It is available as a generic medication. [4] In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million ...
PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They were originally indicated for dyslipidemia of cholesterol and more recently for disorders characterized by high triglycerides.
For example, fibrates are a chemical class of drugs (amphipathic carboxylic acids) that share the same mechanism of action (PPAR agonist), the same mode of action (reducing blood triglyceride levels), and are used to prevent and treat the same disease (atherosclerosis). However, not all PPAR agonists are fibrates, not all triglyceride-lowering ...
Fibrates effectively lower serum triglycerides and raises serum HDL-cholesterol levels. [14] Although clinical benefits of fibrate treatment have been observed, the overall results are mixed and have led to reservations about the broad application of fibrates for the treatment of coronary heart disease , in contrast to statins .
It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well. It was patented in 1958 by Imperial Chemical Industries and approved for medical use in 1963. [1] Clofibrate was discontinued in 2002 due to adverse ...